DDInter147 DDInter782
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Axitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lansoprazole
Axitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Axitinib {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Axitinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Axitinib may cause a minor interaction that can limit clinical effects when taken with Lansoprazole
Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Axitinib may lead to a major life threatening interaction when taken with Atazanavir
Axitinib may lead to a major life threatening interaction when taken with Lomitapide